Single-agent Cobimetinib for Adults With Histiocytic Disorders
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good or bad, Cobimetinib has in
patients with histiocytosis. Cobimetinib is an investigational oral medication that blocks
MEK1.